Citius Pharmaceuticals Inc at Noble Capital Markets Small and Microcap Investor Conference Transcript

Feb 16, 2020 - Feb 20, 2020 / NTS GMT
Leonard Mazur - Citius Pharmaceuticals, Inc. - Director & Chairman of the Board

-- the fact that you're able to come to our meeting, I have realize you had multiple choices here and hopefully you'll find this to be worthwhile.

First of all, we have the usual disclaimer statement, but I do strongly encourage everybody to consult our website as well as for any and all information on the company. We are in Nasdaq and so we are a fully reporting company.

In terms of the company itself, we have some great opportunities. We are different from other pharma companies in effect in a sense that there's some unique aspects to us.

First of all, we have late-stage assets. Our lead asset is a Phase 3 drug. We have a large market opportunity with -- where there are unmet needs and will be, upon approval, the only products in the marketplace. So that makes us, separates us from the rest of the pack.

We do have, as I always like to say, we have an expert team, but what separates us from everybody else is the fact that our team has put in its own money into the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot